NDAQ:SNGX - Post Discussion
Soligenix Inc
> Soligenix HyBryte Phase 3 Flash Study, Significant Results
Post by
HariboSpeedPeak on Jul 20, 2022 2:28pm
Soligenix HyBryte Phase 3 Flash Study, Significant Results
Soligenix’s successful Phase 3 FLASH study evaluating HyBryteTM for the treatment of cutaneous T-cell lymphoma has been published in the Journal of the American Medical Association Dermatology.
The published findings demonstrate that HyBryteTM treatment statistically significantly reduced lesion size, with the treatment response further improving over successive 6-week treatment Cycles. baseline. Lesion response continuously improved with treatment duration. After the first 6-week treatment window, 16% of patients had a response (p=0.04 versus patients with 6weeks of placebo treatment; primary endpoint). This response rate continued to significantly increase to 49% through 18 weeks of treatment (p<0.0001 versus patients with 6-week hypericin or placebo treatment). Throughout the study, HyBryteTM was safe and well-tolerated. Importantly, HyBryteTM was observed to perform similarly against both patch and thicker plaque lesions characteristic of CTCL. Source: https://ir.soligenix.com/2022-07-20-HyBryte-TM-Phase-3-FLASH-Study-for-the-Treatment-of-Cutaneous-T-Cell-Lymphoma-Published-in-JAMA-Dermatology
Be the first to comment on this post